Our data showed that the administration of GRK6 inhibitor GRK6-IN-2 at 0.25 mg/kg twice a week dramatically suppressed the lung metastasis (Fig. 7A and B) and slightly inhibited tumor growth (Fig. 7C) of the MDA-MB231 cell variant. Here, GRK6 is linked to neoplasm.